Jardiance (empagliflozin) - Eli Lilly, Boehringer Ingelheim
SIDIA: Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) - Sep 23, 2026 - P2 | N=16 | Completed | Sponsor: Cantonal Hospital Graubuenden | Recruiting ➔ Completed | N=40 ➔ 16 
Enrollment change • Trial completion • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease
http://clinicaltrials.gov/ct2/show/NCT06435858
 
Sep 23, 2026
 
Prev Next